This is the authors' abstract. We don't add key points for this paper.
COVID-19 infection is always accompanied by a cytokine storm that causes acute respiratory distress syndrome (ARDS).The reduction of pro-inflammatory cytokines is expected to be used for treating COVID-19 patients.Guava (Psidium guajava L.) was believed to have properties as an antioxidant and anti-inflammatory.This study aims to determine the effect of guava extract (PGE) on the ARDS rats model so that it can be used as a PGE treatment for the effects caused by ARDS.This study was conducted on 25 Sprague Dawley rats model in 5 treatment groups.Lipopolysaccharides (LPS) induction was carried out to create ARDS rats model.Determination of pro-inflammatory cytokines in lung Interleukin-18 (IL-18), IL-12 and serum IL-1β, Tumour Necrosis Factor alpha (TNF-α) was performed by ELISA, NOD-, LRR-and Pyrin domain-containing protein 3 (NRLP3) expressions were determined by the quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) method and IL-6, Nuclear factor kappa B (NF-κB) were analysed by immunohisto-chemistry assay.The results showed that PGE contained phenolic compound, daidzin and genistin.The IL-18, IL-12, Il-1β, TNF-α, IL-6, NF-kB and NRLP3 in ARDS model rats were decreased by PGE treatment.In conclusion, PGE can be used as a therapy for treating ARDS by decreasing pro-inflammatory marker.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Priyandoko et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: